New VA Secretary hopes to minimize partisanship, boost morale

Nicholas Leider | | Health Exec | Management
Robert Wilkie

Robert Wilkie

Robert Wilkie—scheduled to be sworn in as the new Secretary of the Department of Veterans Affairs on Monday, July 30—has big plans for reorganizing the upper levels of the agency. His efforts are aimed at boosting flagging morale while ensuring leadership remains nonpartisan.

The Washington Post examined the VA during the transition from previous VA Secretary, David Shulkin, to acting secretary Peter O’Rourke, to Wilkie. John Hoellwart, communications director for AMVETS, an advocacy group, told the Washington Post that the VA has been in flux for some time.

“Over the last year at VA, widely publicized internal political turmoil among senior officials has gotten in the way of serving veterans,” Hoellwarth said, “and it seems like Wilkie is acting decisively to stamp that out on his watch.”

Read the Washington Post story at the link below:

New Veterans Affairs chief plans to reassign, sideline Trump loyalists now in p…

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.